Prognostic value of platelet to lymphocyte ratio in hepatocellular carcinoma: a meta-analysis

作者：Wencong Ma, Ping Zhang, Jun Qi, Litong Gu, Mingcui Zang, Haochen Yao, Xiaoju Shi, Chunli Wang, Ying Jiang · 发表于：Scientific Reports · 年份：2016 · DOI：10.1038/srep35378 · 被引用次数：72 · 研究领域：Inflammatory Biomarkers in Disease Prognosis、Cancer, Lipids, and Metabolism、Hepatocellular Carcinoma Treatment and Prognosis

Abstract This study was designed to evaluate the prognostic value of platelet to lymphocyte ratio (PLR) in hepatocellular carcinoma (HCC). A comprehensive literature search for relevant studies was performed in Web of science, Embase and Pubmed. A total of nine studies with 2017 patients were included in this meta-analysis, and combined hazard ratio (HR) or odds ratio (OR) and 95% confidence intervals (95%CIs) were served as effect measures. Pooled results showed that elevated PLR was associated with poor overall survival (OS) (HR = 1.63, 95%CI: 1.42–1.88, p = 0.000; I2 = 0.0%, Ph = 0.637) and poor disease-free survival (DFS)/recurrence-free survival (RFS) (HR=1.32, 95%CI: 1.15–1.52, p = 0.000; I2 = 19.3%, Ph = 0.287) in HCC patients. In addition, high PLR was not significantly correlated with the presence of vascular invasion, tumor multifocality, poor tumor grade or high level of serum AFP (>400 ng/ml). In conclusion, elevated PLR indicated a poor prognosis for patients with HCC. PLR may be a reliable, easily-obtained, and low cost biomarker with prognostic potential for HCC.